Therapy Areas: Infectious Diseases
Roche expands cyclospora testing portfolio to support US public health response
6 August 2026 - Swiss biotechnology company Roche (SIX: RO, ROG; OTCQX: RHHBY), in collaboration with subsidiary TIB MOLBIOL, announced on Thursday the launch of two new real-time PCR tests to help la...
Decoy Therapeutics expands antiviral platform into Ebola and filovirus research
27 July 2026 - Biotechnology company Decoy Therapeutics Inc (Nasdaq: DCOY) reported on Monday that a D-MAV antiviral candidate demonstrated in vitro activity against wild-type Ebola Zaire virus, expan...
ABL Diagnostics selected to acquire TEXCELL operations
23 July 2026 - ABL Diagnostics (Euronext Paris:ABLD), a provider of molecular biology tests, announced on Thursday that it has been selected by the Évry Commercial Court to acquire the assets a...
Nona Biosciences agrees research collaboration with Medical University of Vienna to advance fully human antibody development for infectious diseases
23 July 2026 - Global biotechnology company Nona Biosciences, a wholly owned subsidiary of HBM Holding Limited (HKEX:02142), announced on Wednesday a research collaboration with the Medical University...
Aptamer Group launches Optimer-based Ebola diagnostic programme
8 July 2026 - Biotechnology company Aptamer Group plc (AIM: APTA) announced on Wednesday that it has commenced development of Optimer binders for a potential rapid diagnostic test targeting the Bundib...
Physiomics secures new contracts worth over GBP200,000
8 July 2026 - Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, declared on Wednesday that it has secured multiple contract awards with a combined estimated ...